According to Amnis, the new patent broadly covers diagnostic uses of multispectral cell imaging in flow or on slides and expands the company’s intellectual property estate to 32 issued US patents plus multiple foreign counterparts.
David Basiji, president and CEO of Amnis, said: “Our technology is a natural fit for the minimally-invasive diagnostic analysis of cells in bodily fluids. ImageStream enables the identification and functional analysis of even extremely rare cells that are indicative of disease, such as circulating tumor cells.
“We are actively collaborating with our clinical partners on the development of diagnostic applications and are pleased that we now have broad intellectual property in multiple diagnostic areas.”